Board of directors
|
Emmanuel Savioz (Co-founder, CFO and Chairman)
Emmanuel Savioz has been in financing and business development since 15 years. He is the Co-founder and Board Member of HYT SA and Preciflex SA. He built a USD 30 million business in Seoul with a local partner for a Swiss industrial company and arranged CHF 62 million of equity financing for high tech companies in Switzerland. Previously, he worked in New York as an investment banker in mergers and acquisitions handling large international transactions in consumer goods and healthcare. Emmanuel Savioz is former member of the Admission Committee of the MBA Program at IMD in Lausanne, Switzerland, and holds an MBA from the Haas School of Business, University of California at Berkeley, USA. |
|
Patrick Berdoz (Co-founder, Board member)
Patrick Berdoz has been a serial entrepreneur for more than 20 years in various innovative sectors (medtech, watch and real estate). He is the Co-founder and Chairman of HYT SA and Preciflex SA. Between 1994 and 2007, he was the CEO and Chairman of Precimed Group which grew from 17 employees to 700. In 1998, he established Precimed in the USA, Japan and then China. He led the successful trade sale of Precimed Group to a publicly traded company in the US. He began his career at 28 as CEO and owner of Viso Medical, an intravenous therapy Company (Neuchâtel, Switzerland) that he sold at age 34 to a French Pharma. Patrick Berdoz is an economist from HEG in Lausanne, Switzerland. |
|
Christophe Bonny, PhD (Co-founder, Board member)
Dr. Bonny has over 20 years’ experience in the field of molecular biology and signalling pathways, has authored over 70 scientific publications and is an inventor on several patents. He works as CSO of Enterome in Paris France since 2016. He discovered D-JNKI, a cell permeable peptide inhibitor of the JNK protein, which formed the basis for the creation of the biotechnology company Xigen SA in 2003. In 2005, he received the Pfizer Research Prize for this discovery and the molecule is currently in Phase III clinical trials for hearing loss. Between 2012 and 2016, he was CSO of Bicycle Therapeutics in Cambridge UK. Between 2006 and 2011, he was CSO of Xigen SA (Switzerland). Previously, he also held the position of Head of Research of the Medical Genetics unit at Lausanne University Hospital (Switzerland) and a prior to this was a Research Fellow at Northwestern University (US). Dr. Bonny obtained a PhD from the University of Neuchâtel (Switzerland), and completed a business and entrepreneurship program at Babson College (US). |